Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.

  title={Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.},
  author={Peter S. Arno and Karen A. Bonuck and Matthew M. Davis},
  journal={The Milbank quarterly},
  volume={73 2},
The Orphan Drug Act provides public subsidies and incentives to spur the development of drugs for rare diseases--drugs that the private sector might otherwise consider unprofitable to produce. Although the act has achieved numerous successes, the high prices and extraordinary sales generated by some orphan drugs lead to a pivotal policy question: how can the act be used to meet the legislative goal of stimulating drug development for small patient populations without resulting in prices that… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 26 references

Obviousness and the Doctrine of Equivalents in Patent Law: Striving for Objective Criteria

S. G. Kalinchak
Catholic University Law Review 43:577. • 1994

Burroughs’ AZT ‘750 Patent Application Based Directly on NIH Test Results

Health News Daily.
(July 19):3-5. • 1993

Drug Industry Musters a Coalition to Do Battle over a Medicaid Bill

R. Pear
New York Times (July 7): 1. • 1993

The Other Drug War: How Industry Exploits Pharm Sub­ sidies

J. Love
American Prospect 14:121-8. • 1993

Against The Odds: The Story o f AIDS Drug Development, Politics & Profits

P. S. Arno, K. L. Feiden.
New York: Harper Collins. • 1992

Implementation of the Orphan Drug Act

S. R. Shulman, B. Bienz-Tadmor, P. S. Seo
Food and Drug Law Journal • 1992

Patent Law Developments in the United States Court of Appeals for the Federal Circuit during 1992

K. H. Colton, M. W. Haas.
American University Law Review 42:909,986. • 1992

Recombinant erythropoietin. Orphan product with a silver spoon.

International journal of technology assessment in health care • 1992

Similar Papers

Loading similar papers…